Immunomodulation

Our immunomodulatory strategy is designed to evade adverse immune responses and allow for repeat dosing

We use transient immunomodulation to prevent immune responses to the adeno-associated virus capsid and the transgene

The clinical application of this approach will be most important in patients who are likely candidates for redosing over the course of their lifetimes

Comprehensive preclinical and clinical data support our immunomodulation approach